A Phase 2 study of intra-articular injection of DE-098 in patients with rheumatoid arthritis

Phase 2

• Conditions: Rheumatoid arthritis

• Registration Number: JPRN-jRCT2080221430
• Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients diagnosed with rheumatoid arthritis

Exclusion Criteria

Participating in other clinical trials
In pregnancy or breast-feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy and safety assessment<br>Assessment of the target joint, adverse events (AE) and adverse drug reactions (ADR)